Lexaria Secures 6 New Patents, Totaling 60
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
Should l Buy LEXX?
The Company now has a total of 60 valid patents granted around most of the major potential markets around the world. The company said, "Lexaria's previous update on patents was issued on October 9, 2025. Since then, we have diligently pursued legal recognition of our innovations leading to intellectual property and are delighted to have enjoyed considerable success through the receipt of 6 new granted patents. In our patent Family #20, Compositions and Methods for Sublingual Delivery of Nicotine, where we have existing granted patents in the US, Canada, and Japan, we have received our first patent in Australia. We have received our first European Union patent in patent Family #21, Compositions and Methods for Treating Hypertension, where we already have 3 US granted patents. Europe is considered the 2nd-largest hypertension market in the world and thus receiving European patent recognition is an important milestone. In our patent Family #24, Compositions and Methods for Treating Epilepsy, we have received 2 new Australian patents and 1 new European Union patent. Our intellectual property in this important Family is now quite robust with a total of 6 US patents; 4 Australian patents; and 1 European Union patent. Finally, in our patent Family #27, Compositions and Methods for Treating Diabetes, we have received 1 new US patent. We now have 2 US patents in this Family which we consider to be quite important given our recent successes in the GLP-1 sector."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEXX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEXX
Wall Street analysts forecast LEXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEXX is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.662
Low
1.50
Averages
1.50
High
1.50
Current: 0.662
Low
1.50
Averages
1.50
High
1.50
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
- Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
- Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
- Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
HC Wainwright Raises Agios Price Target to $62
- Price Target Increase: HC Wainwright & Co. raised the price target for Agios Pharmaceuticals from $48 to $62, with analyst Emily Bodnar maintaining a Buy rating, indicating strong confidence in the company's future growth prospects.
- Market Performance: Agios Pharmaceuticals shares closed at $29.17 on Wednesday, suggesting that despite the price target increase, the current stock price remains undervalued compared to the new target, reflecting market skepticism about its potential.
- Competitive Analysis: In contrast to Agios's price target increase, Lexaria Bioscience's target was cut to $1.5, highlighting significant differences in market outlooks for various biotech companies.
- Capital One Outlook: BTIG raised the price target for Capital One Financial from $264 to $308, with analyst Vincent Caintic maintaining a Buy rating, reflecting optimism about the financial institution's future performance.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Lexaria Achieves Primary Endpoint in GLP-1-H24-4 Study with Significant Safety Results
- Significant Study Results: Lexaria achieved the primary endpoint in the GLP-1-H24-4 study, with all four DehydraTECH test arms demonstrating good safety, as DHT-semaglutide showed a 47.9% reduction in adverse events compared to Rybelsus, laying a solid foundation for future clinical applications.
- Adverse Event Reduction: The DHT-semaglutide formulation exhibited a 54.9% reduction in gastrointestinal adverse events, highlighting its safety advantages, which may attract more pharmaceutical companies to consider its product development.
- Funding Support: Lexaria secured approximately $7.5 million through two transactions since August 31, providing a financial runway for prospective new development opportunities in 2026, thereby enhancing its viability in a competitive market.
- Future Plans: Lexaria intends to pursue follow-on clinical testing to explore the potential of a DehydraTECH + SNAC + semaglutide composition, aiming to further validate its application prospects in diabetes treatment.
See More
Lexaria Bioscience Completes GLP-1 Study, Achieves Nearly 50% Reduction in Side Effects
- Significant Study Results: Lexaria's completed GLP-1-H24-4 study in Australia demonstrated that DHT-semaglutide achieved approximately 47.9% fewer adverse events compared to Novo Nordisk's Rybelsus, indicating its potential in safety and tolerability.
- Reduction in Side Effects: The gastrointestinal adverse events from DHT-semaglutide were reduced by 54.9%, which not only enhances patient experience but also may bolster Lexaria's competitive position in the GLP-1 market.
- Future Research Plans: Lexaria intends to further develop DHT-semaglutide and is considering incorporating salcaprozate sodium in future clinical tests to potentially enhance efficacy and compare it against Rybelsus.
- Data Sharing Agreement: Lexaria will provide the complete dataset from GLP-1-H24-4 to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026, to ensure adequate time for data review.
See More
Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
- Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
- Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
- Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
HC Wainwright Raises Agios Price Target to $62
- Price Target Increase: HC Wainwright & Co. raised the price target for Agios Pharmaceuticals from $48 to $62, with analyst Emily Bodnar maintaining a Buy rating, indicating strong confidence in the company's future growth prospects.
- Market Performance: Agios Pharmaceuticals shares closed at $29.17 on Wednesday, suggesting that despite the price target increase, the current stock price remains undervalued compared to the new target, reflecting market skepticism about its potential.
- Competitive Analysis: In contrast to Agios's price target increase, Lexaria Bioscience's target was cut to $1.5, highlighting significant differences in market outlooks for various biotech companies.
- Capital One Outlook: BTIG raised the price target for Capital One Financial from $264 to $308, with analyst Vincent Caintic maintaining a Buy rating, reflecting optimism about the financial institution's future performance.
See More
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
- Credit Support: Galectin Therapeutics Inc. secured a $10 million credit line, ensuring funding to cover expected expenditures through March 2027, thereby enhancing its R&D capabilities in the NASH cirrhosis treatment space.
- FDA Guidance: The FDA provided written feedback on Galectin's regulatory pathway for belapectin, marking a significant advancement in the company's drug development efforts, which could expedite its product's market entry.
- Market Reaction: Galectin's stock rose by 1% to $4.03 in Wednesday's trading, reflecting investor optimism regarding its financing and FDA support.
- Strategic Implications: This credit line and FDA guidance will provide Galectin with essential funding and regulatory backing in the competitive biopharmaceutical market, aiding its future clinical trials and market launch efforts.
See More
Lexaria Achieves Primary Endpoint in GLP-1-H24-4 Study with Significant Safety Results
- Significant Study Results: Lexaria achieved the primary endpoint in the GLP-1-H24-4 study, with all four DehydraTECH test arms demonstrating good safety, as DHT-semaglutide showed a 47.9% reduction in adverse events compared to Rybelsus, laying a solid foundation for future clinical applications.
- Adverse Event Reduction: The DHT-semaglutide formulation exhibited a 54.9% reduction in gastrointestinal adverse events, highlighting its safety advantages, which may attract more pharmaceutical companies to consider its product development.
- Funding Support: Lexaria secured approximately $7.5 million through two transactions since August 31, providing a financial runway for prospective new development opportunities in 2026, thereby enhancing its viability in a competitive market.
- Future Plans: Lexaria intends to pursue follow-on clinical testing to explore the potential of a DehydraTECH + SNAC + semaglutide composition, aiming to further validate its application prospects in diabetes treatment.
See More
Lexaria Bioscience Completes GLP-1 Study, Achieves Nearly 50% Reduction in Side Effects
- Significant Study Results: Lexaria's completed GLP-1-H24-4 study in Australia demonstrated that DHT-semaglutide achieved approximately 47.9% fewer adverse events compared to Novo Nordisk's Rybelsus, indicating its potential in safety and tolerability.
- Reduction in Side Effects: The gastrointestinal adverse events from DHT-semaglutide were reduced by 54.9%, which not only enhances patient experience but also may bolster Lexaria's competitive position in the GLP-1 market.
- Future Research Plans: Lexaria intends to further develop DHT-semaglutide and is considering incorporating salcaprozate sodium in future clinical tests to potentially enhance efficacy and compare it against Rybelsus.
- Data Sharing Agreement: Lexaria will provide the complete dataset from GLP-1-H24-4 to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026, to ensure adequate time for data review.
See More
